Partnerships Archives

News and Trends 5 Jan 2023

Hummingbird Bioscience and Synaffix to develop ADC program

Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ADCs. Hummingbird Bioscience is a data-driven precision biotherapeutics company using […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Dec 2022

Watch: Zoetis looks for partnerships at BioFIT

Animal health company, Zoetis, has a pipeline of medicines, vaccines, diagnostics and technologies for livestock and pets. Active in more than 100 countries, Zoetis generated revenue of $7.8 billion in 2021, and has approximately 12,100 employees. The company recently announced a collaboration with the partners of the Pastoral Greenhouse Gas Research Consortium, and the New […]

December 29, 2022 - 1 minutemin - By Jim Cornall

News and Trends 23 Dec 2022

Mersana Therapeutics and Merck to develop novel ADCs

Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […]

December 23, 2022 - 3 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 23 Dec 2022

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics

InSitu Biologics, Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics. The company has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix. Once injected, medication elutes from […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Japanese companies look to reduce environmental impact

Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a collaboration to reduce the environmental impact of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentally-friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies […]

December 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Ribbon Biolabs milestone to lead to 2023 market entry

DNA synthesis company Ribbon Biolabs has announced the successful implementation of its InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. The company achieved the milestone in collaboration with HighRes Biosolutions, a laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Ordaōs and Yatiri Bio to tackle AML

Ordaōs has announced a joint development agreement to create new therapeutics for two novel targets in acute myeloid leukemia (AML) with Yatiri Bio. Ordaōs is a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, and Yatiri Bio is a biotechnology company that has developed a proprietary platform that links patient proteomic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Subscribe to our newsletter

Advertise with us

Partnerships

Hummingbird Bioscience and Synaffix to develop ADC program

Watch: Zoetis looks for partnerships at BioFIT

Mersana Therapeutics and Merck to develop novel ADCs

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics

Japanese companies look to reduce environmental impact

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Ribbon Biolabs milestone to lead to 2023 market entry

Ordaōs and Yatiri Bio to tackle AML

Sanofi and Innate Pharma expand natural killer cell deal

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!